Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: Business Wire
Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive BoardEncouraging initial FDA feedback received on lacutamab regulatory pathwayLacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual MeetingIPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumorsPreclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITCCash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2024."I’m honored to join Innate Pharma at such a pivotal moment in its evolution,” said Jonathan Dickinson, Chief Executive Officer of Inna
Show less
Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- Innate Pharma Releases Its 2025 Financial CalendarBusiness Wire
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 [Yahoo! Finance]Yahoo! Finance
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501Business Wire
- Discover 3 Promising Penny Stocks With Over US$90M Market Cap [Yahoo! Finance]Yahoo! Finance
- Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.MarketBeat